Veterinary Biomarkers Market Size & Share 2024 – 2032

Veterinary Biomarkers Market Size

Veterinary Biomarkers Market size was valued at USD 798.5 million in 2023 and is estimated to grow at 9.9% CAGR from 2024 to 2032. The market has seen considerable growth due to the increasing awareness and emphasis on early disease diagnosis and monitoring for animal healthcare.

For instance, according to the American Veterinary Medical Association in April 2022, purebred dogs have a 1.9 times higher relative risk of cancer compared to non-purebred dogs. In veterinary oncology, biomarkers are essential for diagnosis, prognosis, staging, and monitoring of therapeutic outcomes. These factors are expected to increase the adoption of veterinary biomarkers, thereby contributing to the market's growth. Additionally, the growing pet population and the trend of pet humanization are leading to increased spending on animal health.
 

Furthermore, the veterinary field is witnessing an upsurge in research activities and pharmaceutical developments aimed at improving animal health, thereby propelling the demand for veterinary biomarkers and contributing to market expansion. In addition, growing technological advancements in biomarker testing, such as rapid and point-of-care diagnostics, contribute to market growth.
 

Veterinary biomarkers are measurable indicators of normal biological processes, disease states, or responses to treatments in animals. They can include molecules, cells, genes, or other biological characteristics that are objectively measured to assess animal health, diagnose diseases, and monitor therapeutic outcomes. These biomarkers are essential in veterinary medicine for early disease detection, prognosis, drug development, and personalized treatment plans.
 

Veterinary Biomarkers Market Trends

The rising incidence of chronic diseases such as cardiovascular diseases and cancer in animals is a key driver of the market growth. The high prevalence of these diseases necessitates the adoption of biomarkers for early diagnosis, monitoring, and treatment evaluation. The adoption of biomarkers helps veterinarians provide more accurate and timely care, enhancing animal health and welfare.
 

• Chronic kidney disease (CKD) is increasingly common among aging cats, leading to rising demand for diagnostic tests, treatments, and management strategies tailored to feline CKD. Cats exhibit the highest prevalence of renal diseases in veterinary medicine compared to dogs, horses, and cows.
   
• For instance, data from the American Veterinary Medical Association in 2021 indicated CKD prevalence in cats ranging from 2% to 20%, escalating to 30% to 80% among those over 10 to 15 years old. This growing prevalence and emphasis on early detection are expected to drive market growth significantly.
   

Furthermore, increased spending on animal healthcare, rising adoption of pet insurance, advancements in diagnostic technologies, government support, and strategic expansions by key industry players are additional factors driving demand for diagnostic veterinary services.

Veterinary Biomarkers Market Analysis

Based on the animal type, the market is categorized as companion animals and livestock animals. The companion animal segment is set to lead the market, accounting for the largest revenue of USD 523.5 million in 2023, anticipating its dominance throughout the forecast period. The companion animal segment is further categorized into dogs, cats, horses, and other companion animals.
 

• The segment’s dominance is driven by the significant role of biomarkers in diagnosing and managing health conditions in pets such as dogs and cats.
   
• Biomarkers enable early detection, monitoring of treatment responses, and personalized care, contributing to improved animal health outcomes.
   
• The segment's leadership is bolstered by increasing pet ownership rates, rising expenditures on pet healthcare, and advancements in veterinary diagnostics tailored for companion animals.
   
• For example, NAPHIA reported that in 2022, the U.S. and Canada together had 5.4 million insured companion animals, a 22% rise from the 4.4 million in 2021. This surge in insured pets, driven by favorable insurance policies, not only boosts pet adoption rates but also escalates the demand for advanced healthcare services, consequently expanding the adoption of biomarker tests and diagnostic services.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on product type, the veterinary biomarkers market is classified into biomarkers readers and biomarkers kits & reagents. The kits & reagents segment held the largest market share of 62% in 2023 and is expected to maintain dominance throughout the analysis period.

• Veterinarians prioritize sensitive and precise diagnostic approaches facilitated by biomarker test kits. These kits are crucial for tracking disease progression and administering targeted treatments based on biological indicators.
   
• For instance, as reported in MDPI in August 2022, biomarkers show promise in accelerating disease diagnosis, monitoring animal health impacts, and enhancing animal welfare and productivity, potentially revolutionizing veterinary practice. Moreover, cardiac biomarkers like pro-BNP and cardiac troponin I (cTnI) play a critical role in diagnosing and treating progressive cardiac disorders in companion animals, as highlighted in Acta Scientific in June 2022. This increasing adoption of biomarkers for disease diagnosis and treatment in animals is a key driver of segment growth.
   
• Moreover, increasing awareness of biomarker applications in veterinary medicine, particularly in developing countries, has contributed significantly to market expansion in recent years.
   

Based on the disease type, the veterinary biomarkers market is segmented into inflammatory and infectious diseases, cardiovascular diseases, renal diseases, cancer, and other disease type. The inflammatory and infectious diseases segment dominated the market anticipating its dominance throughout the forecast period with a CAGR of 9.8%.
 

• The segment dominance stems from its crucial role in diagnosing and monitoring conditions such as canine parvovirus, feline leukemia, and diverse bacterial infections.
   
• The specific biomarkers for these diseases facilitate early detection, assessment of treatment effectiveness, and effective disease management.
   
• Thus, the significance of precise and prompt diagnostic tools in veterinary medicine, ultimately improving animal health outcomes through targeted therapeutic approaches, which are in high demand among veterinarians and pet owners.
   

Based on the application, the veterinary biomarkers market is segmented into clinical and research. The clinical segment is projected to reach 78.1% by 2032. The clinical segment is further categorized into disease diagnosis and disease monitoring.

• The clinical application segment dominance is driven by its key role in disease diagnosis, treatment monitoring, and prognosis assessment across various animal species. Biomarkers facilitate early diagnosis and precise monitoring of diseases such as cancer, cardiovascular conditions, and infectious diseases in animals.
   
• In addition, the segment's growth is propelled by advancements in biomarker technologies, increasing demand for accurate diagnostic tools, and the expanding adoption of personalized veterinary medicine practices globally.
   

Based on the end-user, the veterinary biomarkers market is segmented into veterinary hospitals, veterinary clinics, research institutes, and reference laboratories. The veterinary clinics segment dominated the market with the highest share in 2023.
 

• Veterinary clinics play a pivotal role in diagnosing and treating animal health issues. They heavily rely on biomarkers for early disease detection, treatment monitoring, and overall health management in animals.
   
• The veterinary clinic segment's significance is propelled by a surge in pet ownership, growing awareness of veterinary care, and technological advancements in diagnostics that bolster clinic capabilities.
   

U.S. dominated the North American veterinary biomarkers market accounting for USD 333.4 million in 2023 and is anticipated to show considerable growth over the analysis period.
 

• The U.S. has the highest rates of pet ownership globally, with over 66% of American households owning dogs or cats. This large companion animal population, coupled with high annual spending on veterinary care (averaging USD 912 per dog and USD 653 per cat), expects to fuel demand for advanced diagnostic solutions thereby expanding the adoption of biomarker-based tests.
   
• Additionally, the presence of major market players like IDEXX Laboratories, Zoetis, and Merck & Co. which are investing heavily in R&D has enabled the development of innovative biomarker products.
   
• Furthermore, the robust regulatory framework from the FDA that supports clinical trials and ensures high quality standards has further bolstered the U.S. market's growth and innovation in veterinary diagnostics.
   
• These factors have collectively positioned the U.S. as the largest market for veterinary biomarkers in North America.
   

Germany exhibited a high growth potential in the European veterinary biomarkers market.
 

• Germany's prominence is driven by its robust animal healthcare infrastructure, stringent regulations around animal welfare, and high pet ownership rates.
   
• According to a recent report from the Central Association of Zoological Specialist Companies (ZZF), a German pet trade and industry association, pets are extremely popular in Germany. In 2023, German households were home to a total of 34.3 million dogs, cats, small animals, and pet birds. This large companion animal population, coupled with the German government's focus on advancing veterinary diagnostics, aimed to fuel the demand for innovative biomarker-based testing solutions in the country.
   
• Additionally, key players in the market have responded to the growing trend of pet humanization by establishing manufacturing and R&D facilities in Germany. This strategic shift allows them to cater to the increasing demand for innovative biomarker-based testing solutions in the country.
   

The Asia Pacific veterinary biomarkers market is poised for rapid growth with a CAGR of 10.4% during the forecast period.
 

• The Asia Pacific market is set for rapid expansion driven by higher pet ownership rates, increased awareness of animal health, and rising prevalence of chronic diseases.
   
• The economic growth and improved access to advanced veterinary care also play significant roles in this growth
  .
• Moreover, government initiatives promoting animal health and investments in veterinary infrastructure are further bolstering market growth.
   
• As a result, the region's burgeoning veterinary diagnostics sector underscores robust demand for comprehensive and dependable in-vitro diagnostic solutions including biomarkers in the market.
   

Veterinary Biomarkers Market Share

The veterinary biomarkers industry features a variety of companies competing to improve diagnostic precision and broaden their range of products. These companies are primarily focusing on strategies such as developing rapid and sensitive biomarker tests, expanding their global footprint, and forming partnerships to advance technology. Moreover, to strengthen their competitive position the companies are intensely focusing on meeting diverse veterinary requirements, spanning from companion animal health to livestock management, while managing regulatory complexities and promoting economically viable solutions.
 

Veterinary Biomarkers Market Companies

Few of the prominent players operating in the veterinary biomarkers industry include:

• Bio-Rad Laboratories, Inc.
• Biomerieux SA
• Bionote USA Inc.
• CUSABIO TECHNOLOGY LLC
• EagleBio
• Gentian Diagnostics ASA
• IDEXX Laboratories Inc.
• Krishgen Biosystems
• Life Diagnostics, Inc.
• Merck KGaA
• Randox Laboratories Ltd. 
• Virbac
• Zoetis Inc.
   

Veterinary Biomarkers Industry News:

• In August 2021, Bionote, launched a new biomarker, TnI, under its Vcheck series. Vcheck Canine TnI is an in vitro diagnostic test designed to quantitatively measure cardiac Troponin I (TnI) levels in canine serum. This test kit accurately assesses the extent of TnI elevation in dogs, providing precise diagnostic information for cardiac health monitoring. This product launch projected an advancement in veterinary diagnostics with cutting-edge solutions.
   
• In June 2020, Roslin Technologies and Destina Genomics launched Vetsina Animal Diagnostics to revolutionize animal treatment and care. Vetsina helps enhance testing speed, detect low biomarker concentrations, utilize existing lab equipment, and transport samples from remote locations focusing on microRNAs, valuable biomarkers for infections and diseases. This initiative expanded the accessibility of advancement in veterinary diagnostics solutions across remote locations.
   

The veterinary biomarkers market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Animal Type

• Companion animals
  • Dogs
  • Cats
  • Horses
  • Other companion animals
• Livestock animals
  • Cattle
  • Poultry
  • Swine
  • Other livestock animals

Market, By Product Type

• Biomarker readers
• Biomarker kits & reagents

Market, By Disease Type

• Inflammatory and infectious diseases
• Cardiovascular diseases
• Renal diseases
• Cancer
• Other disease types

Market, By Application

• Clinical
  • Disease diagnosis
  • Disease monitoring
• Research

Market, By End-user

• Veterinary hospitals
• Veterinary clinics
• Research institutes
• Reference laboratories

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • The Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa